Valbiotis SA (ALVAL.PA)
EUR 1.36
(-1.59%)
EUR 1.36
(-1.59%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.36 Million EUR | 40.16% |
| 2022 | -12.31 Million EUR | -41.83% |
| 2021 | -8.68 Million EUR | -126.72% |
| 2020 | -3.82 Million EUR | 30.43% |
| 2019 | -5.5 Million EUR | -10.81% |
| 2018 | -4.96 Million EUR | -103.32% |
| 2017 | -2.44 Million EUR | -311.97% |
| 2016 | -593 Thousand EUR | 19.76% |
| 2015 | -739 Thousand EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.5 Million EUR | 0.0% |
| 2023 Q4 | -5.44 Million EUR | 0.0% |
| 2023 FY | -7.36 Million EUR | 40.16% |
| 2023 Q2 | -1.92 Million EUR | 0.0% |
| 2022 Q4 | -7.21 Million EUR | 0.0% |
| 2022 FY | -12.31 Million EUR | -41.83% |
| 2022 Q2 | -5.09 Million EUR | 0.0% |
| 2021 FY | -8.68 Million EUR | -126.72% |
| 2021 Q2 | -3.46 Million EUR | 0.0% |
| 2021 Q4 | -5.21 Million EUR | 0.0% |
| 2020 Q4 | -898 Thousand EUR | 0.0% |
| 2020 FY | -3.82 Million EUR | 30.43% |
| 2020 Q2 | -2.93 Million EUR | 0.0% |
| 2019 FY | -5.5 Million EUR | -10.81% |
| 2019 Q4 | -2.78 Million EUR | 0.0% |
| 2019 Q2 | -2.72 Million EUR | 0.0% |
| 2018 FY | -4.96 Million EUR | -103.32% |
| 2018 Q4 | -3.02 Million EUR | 0.0% |
| 2018 Q2 | -1.94 Million EUR | 0.0% |
| 2017 Q4 | -2.07 Million EUR | 0.0% |
| 2017 FY | -2.44 Million EUR | -311.97% |
| 2017 Q2 | -367 Thousand EUR | 0.0% |
| 2016 Q1 | -154 Thousand EUR | 0.0% |
| 2016 FY | -593 Thousand EUR | 19.76% |
| 2016 Q4 | -399 Thousand EUR | 0.0% |
| 2016 Q2 | -194 Thousand EUR | -25.97% |
| 2015 Q4 | -154 Thousand EUR | 0.0% |
| 2015 FY | -739 Thousand EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -109.437% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 95.013% |
| Adocia SA | -21.16 Million EUR | 65.183% |
| Aelis Farma SA | -5.07 Million EUR | -45.096% |
| Biophytis S.A. | -17.02 Million EUR | 56.725% |
| Advicenne S.A. | -7.03 Million EUR | -4.793% |
| genOway Société anonyme | 1.56 Million EUR | 570.025% |
| IntegraGen SA | -171.39 Thousand EUR | -4198.742% |
| Medesis Pharma S.A. | -3.95 Million EUR | -86.085% |
| Neovacs S.A. | -8.74 Million EUR | 15.731% |
| NFL Biosciences SA | -3.74 Million EUR | -96.717% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 9406.673% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -132.36% |
| Sensorion SA | -22.06 Million EUR | 66.605% |
| Theranexus Société Anonyme | -6.82 Million EUR | -7.909% |
| TME Pharma N.V. | -6.73 Million EUR | -9.382% |
| TheraVet SA | -1.57 Million EUR | -369.088% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 63.783% |
| argenx SE | -272.91 Million EUR | 97.3% |
| BioSenic S.A. | -28.77 Million EUR | 74.397% |
| Celyad Oncology SA | -8.44 Million EUR | 12.784% |
| DBV Technologies S.A. | -67.26 Million EUR | 89.047% |
| Galapagos NV | 211.69 Million EUR | 103.48% |
| Genfit S.A. | -28.89 Million EUR | 74.5% |
| GeNeuro SA | -14.75 Million EUR | 50.071% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | 52.094% |
| Innate Pharma S.A. | -7.57 Million EUR | 2.668% |
| Inventiva S.A. | -110.42 Million EUR | 93.328% |
| MaaT Pharma SA | -19.71 Million EUR | 62.631% |
| MedinCell S.A. | -25.03 Million EUR | 70.573% |
| Nanobiotix S.A. | -39.7 Million EUR | 81.441% |
| Onward Medical N.V. | -36.18 Million EUR | 79.636% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -119.747% |
| OSE Immunotherapeutics SA | -23 Million EUR | 67.969% |
| Oxurion NV | -18.96 Million EUR | 61.158% |
| Pharming Group N.V. | -9.75 Million EUR | 24.482% |
| Poxel S.A. | -35.09 Million EUR | 79.003% |
| GenSight Biologics S.A. | -26.22 Million EUR | 71.899% |
| Transgene SA | -22.32 Million EUR | 67.001% |
| Financière de Tubize SA | 88.15 Million EUR | 108.358% |
| UCB SA | 343 Million EUR | 102.148% |
| Valneva SE | -101.42 Million EUR | 92.736% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 74.003% |